In-111 rosopatamab tetraxetan

Phase 2Biologic

In-111 rosopatamab tetraxetan is one of 10 biologic programs targeting Castration-resistant Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Castration-Resistant Prostate CancerRecruiting

Castration-Resistant Prostate CancerPhase 2

Recruiting

Competition

Competitive Landscape

9 competitors in Castration-Resistant Prostate Cancer

#DrugCompanyPhaseTrials

Xtandi

Astellas

Phase 2

1 2

Keytruda

Merck & Co.

Phase 2

1 3

Depo-Testosterone

AAzurity Pharmaceuticals

Phase 2

1 4

Delatestryl

AAntares Pharma Inc.

Phase 2

1 5

Zytiga

Johnson & Johnson

Preclinical

1 6

Lynparza

AstraZeneca

Preclinical

1 7

Ptvg-HP

UUniversity of Wisconsin, Madison

Phase 2

1 8

Ptvg-AR

UUniversity of Wisconsin, Madison

Phase 2

1 9

In-111 rosopatamab tetraxetan

CConvergent Therapeutics

Phase 2

1 10

BL-B01D1

SSichuan Baili Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Castration-Resistant Prostate Cancer

NCT06549465

Clinical

Trials by Indication[1]

Castration-resistant Prostate Cancer1 trial

A Phase 2, Open-label Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer

Recruiting·CConvergent Therapeutics·Phase 2·NCT06549465·93 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for In-111 rosopatamab tetraxetan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — In-111 rosopatamab tetraxetan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for In-111 rosopatamab tetraxetan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Convergent Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: CConvergent Therapeutics

In-111 rosopatamab tetraxetan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Castration-resistant Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News